Morrison Briggs's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Jul 5, 2022
- Accession no.
- 0001562180-22-005475
- Filed
- Jul 5, 2022
- Trade date
- Jul 1, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.18M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morrison BriggsCIK 0001654430 | Director, Officer (President, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock | MOption exerciseAcquired | +62,292 | $7.20 | +$448,502.4 | 80,128 | Direct | |
| Jul 1, 2022 | Common Stock | SSaleDisposed | −62,292 | $19.00F2 | −$1,183,548 | 17,836 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock | MOption exerciseDisposed | −62,292 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $18.61 to $19.38
Referenced by the price of 1 transaction in Table I.